1/7/2021 8:24:40 AM
Revance Maintains Strong Balance Sheet; Reaffirms Its Expectations To Be Funded Into 2023
12/17/2020 8:09:14 AM
Revance Therapeutics Reports Positive Efficacy And Duration Results From Phase 2 Upper Facial Lines Study
12/16/2020 8:37:00 AM
Revance Therapeutics To Relocate Its Headquarters From Silicon Valley's Newark, California, To Nashville, Tennessee.
11/25/2020 8:34:56 AM
Revance : FDA Defers Approval Of DaxibotulinumtoxinA For Injection In Glabellar Lines Due To Travel Restrictions
8/11/2020 8:41:05 AM
Revance Therapeutics Announces Publication Of Two
separate Peer-reviewed Articles In Dermatologic Surgery
5/19/2020 8:07:05 AM
Revance Agrees To Acquire HintMD And Its Proprietary Fintech Platform For Aesthetic Practices
5/1/2020 8:33:48 AM
Revance And Mylan Biosimilar To BOTOX(r) Program Decision To Extend Beyond April 30, 2020
2/6/2020 8:16:24 AM
Revance Therapeutics Says BLA For DAXI In Treatment Of Moderate To Severe Glabellar Lines Accepted For Review By US FDA
12/4/2019 7:45:59 AM
Revance Therapeutics Prices Public Offering Of 6.5 Mln Shares At $17/Shr
12/3/2019 4:08:08 PM
Revance Announces Proposed Public Offering Of Common Stock
12/2/2019 8:14:30 AM
Revance Therapeutics Promotes Dustin Sjuts To Role Of Chief Commercial Officer, Aesthetics & Therapeutics
11/25/2019 8:04:59 AM
Revance Submits BLA To The FDA For DAXI To Treat Glabellar (Frown) Lines
11/4/2019 8:06:21 AM
Revance Announces Publication Of SAKURA 1 And SAKURA 2 Results In Plastic And Reconstructive Surgery